CACNA1D

Voltage-dependent L-type calcium channel subunit alpha-1D · Q01668 · CACNA1D on Sugi Atlas →

66,496 patent compounds predicted against CACNA1D, 43,368 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
Nisoldipine (SCHEMBL39779)	1.00	9/20
Nisoldipine (SCHEMBL39780)	1.00	9/20
Nitrendipine (SCHEMBL38972)	0.91	9/20
(R)-Nitrendipine (SCHEMBL38973)	0.91	9/20
(S)-Nitrendipine (SCHEMBL120983)	0.91	9/20
Nimodipine (SCHEMBL34041)	0.82	8/20
(S)-Nimodipine (SCHEMBL34042)	0.82	8/20
Nimodipine (SCHEMBL142534)	0.81	8/20
SCHEMBL194784	0.51	8/20
Cilnidipine (SCHEMBL25550)	0.69	7/20
Cilnidipine (SCHEMBL25551)	0.69	7/20
SCHEMBL25549	0.62	7/20
Hydrochloric Acid (SCHEMBL335331)	0.55	7/20
SCHEMBL336826	0.54	7/20
Amperozide (SCHEMBL340961)	0.67	5/20
SCHEMBL265956	0.48	5/20
SCHEMBL66633	0.42	5/20
SCHEMBL202183	0.73	4/20
Difluanine (SCHEMBL124263)	0.54	4/20

Clinical trials — most relevant to CACNA1D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)	PHASE1	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
International CRDS Registry	nan	RECRUITING
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
Verapamil in Supraclavicular Brachial Plexus Block	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism	nan	COMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Sevoflurane Effect on Left Atrial Performance: A Transoesophageal Echocardiographic Study	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Postoperative Pain Alleviation in Open Heart Surgery	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA1D binder may also engage these)

Protein	Name	Similarity
O73700	—	1.000	O73700 →
P22002	—	1.000	P22002 →
Q02789	—	1.000	Q02789 →
O57483	—	1.000	O57483 →
Q99244	—	0.999	Q99244 →
P07293	—	0.998	P07293 →
O35505	—	0.998	O35505 →
C9D7C2	—	0.998	C9D7C2 →
CACNA1C	Voltage-dependent L-type calcium channel subunit alpha-1C	0.998	landscape →
Q25452	—	0.997	Q25452 →
P27732	—	0.997	P27732 →
P91645	—	0.996	P91645 →
CACNA1A	Voltage-dependent P/Q-type calcium channel subunit alpha-1A	0.996	landscape →
Q05152	—	0.995	Q05152 →
P22316	—	0.995	P22316 →
Q99246	—	0.994	Q99246 →
P15381	—	0.994	P15381 →
P56698	—	0.993	P56698 →
Q01815	—	0.991	Q01815 →
Q28644	—	0.991	Q28644 →
O08562	—	0.991	O08562 →
Q62205	—	0.990	Q62205 →
Q02343	—	0.990	Q02343 →
O42398	—	0.990	O42398 →
KCNA2	Potassium voltage-gated channel subfamily A member 2	0.990	landscape →
SCN7A	Sodium channel protein type 7 subunit alpha	0.990	landscape →
P02719	—	0.990	P02719 →
O55017	—	0.989	O55017 →
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	0.989	landscape →
A2APX8	—	0.989	A2APX8 →